移植物肾尿路上皮癌的分子分析:罕见病例报告。
Urothelial carcinoma of the graft kidney with molecular analyses: a rare case report.
机构信息
Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
出版信息
Diagn Pathol. 2021 Jun 14;16(1):53. doi: 10.1186/s13000-021-01109-z.
BACKGROUND
Malignancy after transplantation is a leading cause of death among kidney transplant recipients. However, donor-derived malignancies are rare. We report a case of a high grade papillary urothelial carcinoma arising in a transplanted kidney.
CASE PRESENTATION
A 62-year-old female who received a kidney transplantation more than 30 years ago presented with urinary tract infection, acute renal failure, and hydronephrosis of the transplant kidney. Anterograde nephrostogram showed a large filling defect in the lower pole of the transplant kidney and in the proximal 3-4 cm of the ureter. A biopsy from the renal pelvic mass showed a high grade urothelial carcinoma. She underwent an anterior exenteration, resection of both transplant and native kidneys and bilateral pelvic lymph node dissection. Pathologic examination showed a high grade papillary urothelial carcinoma which appeared to arise in the pelvis of the graft kidney, involve the graft ureter and native urinary bladder. The tumor had metastasized to one left obturator lymph node but spared the two native kidneys and ureters. Short tandem repeat (STR) analysis confirmed the tumor to be of donor origin. Next-generation sequencing identified amplification of TERT and loss of CDKN2A/CDKN2B in the primary tumor.
CONCLUSION
While it is known that transplant recipients have an increased risk of urothelial carcinoma compared to the general population, the lack of the well-documented risk factors, such as older age at transplantation, BK polyomavirus infection, and prolonged post-transplantation history and dissemination of the tumor in this case shed light on the de novo tumorigenesis of the graft kidney within the host microenvironment. Amplification of Telomerase reverse transcriptase (TERT) and loss of cyclin dependent kinase inhibitor 2A/2B (CDKN2A/CDKN2B) detected in the tumor by next gene sequencing suggests that they may play an important role in this case.
背景
移植后恶性肿瘤是肾移植受者死亡的主要原因。然而,供体来源的恶性肿瘤很少见。我们报告了一例在移植肾中发生的高级别乳头状尿路上皮癌。
病例介绍
一名 62 岁女性,30 多年前接受了肾移植,因尿路感染、急性肾衰竭和移植肾积水就诊。顺行尿路造影显示移植肾下极和输尿管近端 3-4cm 处有大的充盈缺损。肾盂肿块活检显示高级别尿路上皮癌。她接受了前盆腔脏器切除术、移植肾和原肾切除术以及双侧盆腔淋巴结清扫术。病理检查显示高级别乳头状尿路上皮癌,似乎起源于移植物肾盂,累及移植物输尿管和原膀胱。肿瘤已转移至左侧闭孔淋巴结,但未累及两个原肾和输尿管。短串联重复(STR)分析证实肿瘤来自供体。下一代测序确定原发性肿瘤中 TERT 扩增和 CDKN2A/CDKN2B 缺失。
结论
虽然已知与普通人群相比,移植受者患尿路上皮癌的风险增加,但在这种情况下,缺乏有充分记录的风险因素,如移植时年龄较大、BK 多瘤病毒感染以及移植后病史延长,肿瘤的播散,提示宿主微环境中移植物肾脏的新发肿瘤发生。肿瘤中通过下一代基因测序检测到的端粒酶逆转录酶(TERT)扩增和细胞周期蛋白依赖性激酶抑制剂 2A/2B(CDKN2A/CDKN2B)缺失表明它们可能在本例中起重要作用。